Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SYNCOM FORMULATIONS Gains 7%; BSE HEALTHCARE Index Down 0.0%
Tue, 16 Jul 9:32

SYNCOM FORMULATIONS Gains 7%; BSE HEALTHCARE Index Down 0.0%Image source: Ivcandy/www.istockphoto.com

SYNCOM FORMULATIONS share price has zoomed 7% and is presently trading at Rs 17.2.

Meanwhile, the BSE HEALTHCARE index is at 38,775.0 .

Among the top gainers in the BSE HEALTHCARE index today are ALEMBIC PHARMA (up 3.4%) and GSK Pharma (up 3.1%).

MAX HEALTHCARE INSTITUTE (down 1.1%) and Dr. Reddys (down 0.8%) are among the top losers today.

Over the last one year, SYNCOM FORMULATIONS has moved up from Rs 7.3 to Rs 17.2, registering a gain of Rs 9.9 (up 136.5%).

On the other hand, the BSE HEALTHCARE index has moved up from 26,286.8 to 38,775.0, registering a gain of 47.5% during the last 12 months.

The top gainers among the BSE HEALTHCARE index stocks during this same period were Glenmark Pharma (up 109.2%), Cadila Healthcare (up 100.2%) and Lupin (up 94.0%).

Must See: These Segments are Witnessing Incredible Growth with Modi's Push

What About the Benchmark Indices?

The BSE Sensex is at 80,777.1 (up 0.1%).

The top gainers among the BSE Sensex today are Bharti Airtel (up 1.2%) and Maruti Suzuki (up 1.1%). The most traded stocks in the BSE Sensex are Tata Steel and NTPC.

In the meantime, NSE Nifty is at 24,622.5 (up 0.2%). BPCL and HDFC LIFE INSURANCE are among the top gainers in NSE NIFTY.

Over the last 12 months, the BSE Sensex has moved up from 65,393.9 to 80,777.1, registering a gain of 15,383.2 points (up 23.5%).

SYNCOM FORMULATIONS Financial Update...

SYNCOM FORMULATIONS net profit fell 12.6% YoY to Rs 74 million for the quarter ended March 2024, compared to a profit of Rs 85 million a year ago. Net sales rose 22.3% to Rs 746 million during the period as against Rs 610 million in January-March 2023.

For the year ended March 2023, SYNCOM FORMULATIONS reported 1.4% increase in net profit to Rs 201 million compared to net profit of Rs 198 million during FY22. Revenue of the company grew 2.1% to Rs 2,243 million during FY23.

The current Price to earnings ratio of SYNCOM FORMULATIONS, based on rolling 12 month earnings, stands at 63.8.


Equitymaster requests your view! Post a comment on "SYNCOM FORMULATIONS Gains 7%; BSE HEALTHCARE Index Down 0.0%". Click here!